ClinicalTrials.Veeva

Menu

Ussing Experiments to Evaluate the Role of Medication-induced Microscopic Colitis

Maastricht University Medical Centre (MUMC) logo

Maastricht University Medical Centre (MUMC)

Status

Completed

Conditions

Microscopic Colitis

Treatments

Other: Ussing experiment

Study type

Interventional

Funder types

Other

Identifiers

NCT02303132
NL48505.068.14

Details and patient eligibility

About

Medication use, especially NSAIDs and PPIs, prior to diagnosis is considered a risk factor for MC development. However, the exact pathophysiological mechanism is unclear. It is hypothesized that NSAIDs, PPIs, and SSRIs may have an effect on the colon permeability, due to an idiosyncratic reaction which results in a local immune response. MC patients are considered to be susceptible hosts, prone to react on administration of abovementioned drugs. In order to test this hypothesis and to generate new insights in the pathophysiology of MC, we want to perform an Ussing chamber experiment using fresh colon tissue samples. The primary objective is to assess ex vivo the effect of NSAIDs and PPIs on epithelial permeability of colon biopsy specimens of MC and non-MC patients, using the Ussing chamber system

Enrollment

12 patients

Sex

All

Ages

18 to 90 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • The indication for colonoscopy is a relapse of MC (active) / MC in remission (remission) / no MC (control)
  • Patient is not treated with NSAIDs / PPI / SSRI in week before inclusion

Exclusion criteria

  • Age below 18 years at the time of diagnosis
  • Use of anticoagulants or immunosuppressive drugs
  • Severe co-morbidities hindering an endoscopic procedure
  • A previous history of any type of chronic colitis, IBS, IBD, colon carcinoma or (partial) colectomy
  • A recent (last year) diagnosis of infectious diarrhea or radiation proctitis.
  • Use of medication known to influence intestinal permeability
  • Excessive alcohol usage (>20 standard units per week)
  • Not capable of signing an informed consent

Trial design

Primary purpose

Basic Science

Allocation

Non-Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

12 participants in 3 patient groups

Active MC
Other group
Description:
Patients with active MC will be included
Treatment:
Other: Ussing experiment
MC in remission
Other group
Description:
Patients with MC in remission will be included
Treatment:
Other: Ussing experiment
Controls
Other group
Description:
Patients without MC will be included
Treatment:
Other: Ussing experiment

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems